ClinicalTrials.gg
CompletedNCT02076100Updated Dec 24, 2018Results posted

Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

A Phase 1 interventional study of Ruzasvir in Hepatitis C Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Hepatitis C by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C · Merck & Co., Inc.

Enrollment
51st of 69
22 · median 60
Started
2014
with 11 others
Phase 1
28 of 92
none open now
Registered
68th of 92
by date

Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 51st largest by enrollment of the 69 interventional ones that give a count, is one of 12 that started in 2014, is one of 28 in phase 1, and was the 68th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 92 studies in Hepatitis C by Merck & Co., Inc is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 92 studies in Hepatitis C by Merck & Co., Inc as a file.
02

Study summary

This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of Ruzasvir. Part I will be for participants with hepatitis C virus (HCV) genotype 3 (GT3) and will run first: Part II will be for participants with HCV genotype 1a (GT1a), and Part III will be for participants with HCV genotype 2b (GT2b). Parts II and III may run concurrently. The primary study hypothesis is that a safe and tolerable dose of Ruzasvir that reduces viral load will be found to support further clinical investigation.

03

Conditions studied

  • Hepatitis C Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >=18 to\<=37 kg/m\^2
  • In general good health, except for infection
  • Clinical diagnosis of chronic HCV infection exclusively GT3 (Panels A-D) or exclusively GT1a (Panels E-F), or exclusively GT2b (Panels G-H).
  • Must agree to follow the smoking restrictions defined by the CRU
  • Must agree to use an acceptable method of during the study and for 90 days after the last dose of ruzasvir

Exclusion criteria

Exclusion Criteria:

  • endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases
  • History of clinically significant hepatic disease, Gilbert's disease or biliary tract disease
  • History of cancer () with the exception of adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or successfully-treated malignancies ≥10 years prior to screening
  • History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
  • Positive for or (HIV)
  • Major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening
  • Participated in another trial within 4 weeks prior to the screening visit
  • >=470 msec (for males) or >= 480 msec (for females)
  • Unable to refrain from or anticipates use of any medication (prescription and/or non-prescription) or herbal remedies beginning approximately 2 weeks prior to first study drug dose, throughout the trial until the post-trial visit
  • Consumes >2 glasses of alcoholic beverages per day
  • Regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 12 months
  • Evidence or history of chronic hepatitis not caused by
  • Previous treatment with other HCV NS5A inhibitors such as MK-8742, daclatasvir, or MK-8325
  • Treatment with other HCV therapies such as the HCV protease
  • Evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (Metavir score >=3)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Part I GT3 Participants

    Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

    Drug: Ruzasvir

  • Experimental
    Part II GT1a Participants

    Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

    Drug: Ruzasvir

  • Experimental
    Part III GT2b Participants

    Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

    Drug: Ruzasvir

Interventions

  • Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

    Also known as: MK-8408

06

What researchers measure

Primary outcomes

  1. Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline

    Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.

    Time frame: Baseline and up to Day 5

  2. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 61 days

  3. Number of Participants Who Discontinued Study Drug Due To An AE

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 5 days

07

Results

Posted Nov 28, 2018

Participant flow

Males or females of non-child bearing potential, with verified Hepatitis C virus (HCV) infection with genotype (GT) GT1a, GT2b or GT3 between the ages of 18 and 65 years (inclusive) were enrolled in this trial. In the GT1a group, one participant was later determined to be GT1b.

Participant flow — Overall Study
MilestoneRuzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1a
Started3333334
Completed3333334
Not completed0000000

Outcome measures

PrimaryMaximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline

Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.

Time frame:
Baseline and up to Day 5
Reported as:
Least squares mean · log10 IU/mL
Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline
log10 IU/mLRuzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1aRuzasvir 60 mg - GT1b
Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline2.84 (1.94 to 3.74)3.03 (2.13 to 3.94)3.36 (2.46 to 4.26)1.81 (0.90 to 2.71)3.82 (3.15 to 4.50)3.62 (2.95 to 4.30)3.63 (2.46 to 4.81)3.82 (NA to NA)
PrimaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 61 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsRuzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1a
Number of Participants Who Experienced One or More Adverse Events (AEs)0021222
PrimaryNumber of Participants Who Discontinued Study Drug Due To An AE

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 5 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due To An AE
ParticipantsRuzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1a
Number of Participants Who Discontinued Study Drug Due To An AE0000000

Adverse events

Collected over Up to 61 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruzasvir 10 mg - GT30/3 (0%)0/3 (0%)0/3 (0%)
Ruzasvir 30 mg - GT30/3 (0%)0/3 (0%)0/3 (0%)
Ruzasvir 60 mg - GT30/3 (0%)0/3 (0%)2/3 (66.7%)
Ruzasvir 120 mg - GT30/3 (0%)0/3 (0%)1/3 (33.3%)
Ruzasvir 10 mg - GT2b0/3 (0%)0/3 (0%)2/3 (66.7%)
Ruzasvir 60 mg - GT2b0/3 (0%)0/3 (0%)2/3 (66.7%)
Ruzasvir 60 mg - GT1a0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRuzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1a
Feeling hotGeneral disorders0/30/32/30/30/30/30/4
Back painMusculoskeletal and connective tissue disorders0/30/32/30/30/30/30/4
DiarrhoeaGastrointestinal disorders0/30/30/31/30/30/30/4
NauseaGastrointestinal disorders0/30/31/30/31/30/30/4
Catheter site phlebitisGeneral disorders0/30/30/30/31/30/30/4
ContusionInjury, poisoning and procedural complications0/30/30/30/30/31/30/4
Procedural painInjury, poisoning and procedural complications0/30/30/30/30/31/30/4
MyalgiaMusculoskeletal and connective tissue disorders0/30/30/30/31/30/30/4
HeadacheNervous system disorders0/30/30/30/30/31/31/4
EpistaxisRespiratory, thoracic and mediastinal disorders0/30/30/30/31/30/30/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ruzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1aTotal
Mean40.7 ± 6.536.0 ± 3.538.0 ± 10.440.7 ± 13.656.3 ± 2.154.0 ± 6.248.5 ± 6.245.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Ruzasvir 10 mg - GT3Ruzasvir 30 mg - GT3Ruzasvir 60 mg - GT3Ruzasvir 120 mg - GT3Ruzasvir 10 mg - GT2bRuzasvir 60 mg - GT2bRuzasvir 60 mg - GT1aTotal
Female10001103
Male233322419
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Nov 2015, 19 months.

Results were first posted in Nov 2018, 3 years after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Hepatitis C, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 19 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 4 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 3, 2014
StartActual
Mar 27, 2014
Primary completionActual
Nov 15, 2015
CompletionActual
Nov 15, 2015
Results first posted
Nov 28, 2018
Last update
Dec 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02076100
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Mar 27, 2014
Primary completion
Nov 15, 2015
Completion
Nov 15, 2015
Results posted
Nov 28, 2018
Last update
Dec 24, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzasvir

Start the discussion